Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSCOPE phase II preoperative chemoradiotherapy study in resectable oesophageal adenocarcinoma
2012-000640-10Phase 2Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Dec 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in esophageal adenocarcinoma (EAC) comparing Oxaliplatin + capecitabine chemoradiotherapy arm with Paclitaxel + carboplatin chemoradiotherapy arm (2 arms). Primary endpoint: Pathological complete response rate. Started Dec 2012; status: completed.
02
Drugs
capecitabineoxaliplatinpaclitaxelcarboplatin
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2012-000640-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000640-10.